Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Vimian Group AB ( (SE:VIMIAN) ).
Vimian Group AB has announced the release of its Interim Report for the second quarter of 2025, scheduled for publication on July 18. The company will host an audiocast for investors, analysts, and media, where CEO Patrik Eriksson and CFO Carl-Johan Zetterberg Boudrie will present and discuss the report. This event underscores Vimian’s commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian is a global animal health company that operates in four key areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company is committed to providing innovative solutions for animal health professionals and pet owners worldwide. Headquartered in Stockholm, Sweden, Vimian serves over 17,000 veterinary clinics and laboratories in more than 80 markets, with a workforce of 1,200 employees and annual revenues of approximately EUR 375 million.
YTD Price Performance: 5.03%
Average Trading Volume: 456,461
Current Market Cap: SEK21.76B
For an in-depth examination of VIMIAN stock, go to TipRanks’ Overview page.